Genomictree Inc. (KOSDAQ:228760)
South Korea · Delayed Price · Currency is KRW 16,960
+200 (1.19%)
Apr 10, 2026, 3:30 PM KST
Genomictree Revenue
In the year 2025, Genomictree had annual revenue of 3.76B KRW with 59.17% growth. Genomictree had revenue of 825.62M in the quarter ending December 31, 2025, with 0.14% growth.
Revenue
3.76B
Revenue Growth
+59.17%
P/S Ratio
109.46
Revenue / Employee
n/a
Employees
n/a
Market Cap
411.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.76B | 1.40B | 59.17% |
| Dec 31, 2024 | 2.36B | -1.06B | -30.89% |
| Dec 31, 2023 | 3.42B | -26.45B | -88.56% |
| Dec 31, 2022 | 29.87B | 24.73B | 481.09% |
| Dec 31, 2021 | 5.14B | 3.90B | 314.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Holdings | 2.45T |
| Bioneer | 330.11B |
| Medy-Tox | 247.29B |
| BINEX | 168.47B |
| GC Cell | 165.52B |
| JETEMA, | 76.90B |
| HLB Therapeutics | 69.56B |
| SillaJen | 9.23B |